Placental Stem Cell Therapy for Neurological Disorders Market Size is valued at USD 384.09 Mn in 2022 and is predicted to reach USD 2,049.44 Mn by the year 2031 at a 20.6% CAGR during the forecast period for 2023-2031.
Placental stem cell therapy for neurological disorders involves using stem cells derived from the placenta to treat various conditions affecting the nervous system. While this field of regenerative medicine shows promise, it is still an area of ongoing research, and clinical applications are not yet widely established. Increased awareness campaigns and educational efforts about the benefits and potential of placental stem cell therapies are raising awareness among healthcare professionals and patients, driving acceptance and adoption. Collaborations between research institutions, healthcare facilities, and biotech companies facilitate translating scientific discoveries into clinical applications, fostering market growth. Patients are increasingly seeking regenerative therapies that offer the potential for improved outcomes and a better quality of life, driving the demand for placental stem cell treatments.
Additionally, stringent regulatory requirements and approval processes can hinder the development and commercialization of placental stem cell therapies for neurological disorders. Meeting these regulatory standards can be time-consuming and costly. The availability of limited clinical data and long-term safety and efficacy data for placental stem cell therapies in treating neurological disorders may raise concerns among healthcare professionals and patients.
Competitive Landscape
Some Major Key Players In The Placental Stem Cell Therapy for Neurological Disorders Market:
- Mesoblast Ltd.
- Pleurite Therapeutic
- Remeron Group
- AthersysInc
- Cordlife India
- Life Cell International Pvt. Ltd
- Cryo-Cell International Inc.
- CBR Systems
- Cellularity Inc.
- Cynara
- Others
Market Segmentation:
The placental stem cell therapy for neurological disorders market is segmented as product and application. Based on type, the market is segmented as allogeneic placental stem cell therapy and autologous placental stem cell therapy. The end users segment consists of hospitals & speciality clinics, clinics, research organizations and research institutes & academics.
Based On The Product, The Autologous Stem Cell Segment Is A Major Contributor In The Placental Stem Cell Therapy For Neurological Disorders Market
The autologous stem cell category will hold a major share in the global placental stem cell therapy for neurological disorders market 2022. Autologous stem cell therapy may provide the potential for long-term benefits, as the patient's cells are more likely to integrate and persist in the body without rejection. Autologous therapies eliminate the risk of disease transmission from donor-derived cells, which can be a concern with allogeneic therapies. This safety advantage is particularly crucial for patients with neurological disorders.
Hospital And Speciality Clinics Segment To Witness Growth At A Rapid Rate
The hospitals & speciality clinics segment is growing rapidly in the global placental stem cell therapy for neurological Disorders market. Hospitals often have specialized medical teams with expertise in neurological disorders. Patients seek out hospitals for placental stem cell therapy due to the availability of skilled neurologists and neurosurgeons who can assess their conditions and recommend appropriate treatments. Hospitals typically have state-of-the-art diagnostic and treatment facilities, including advanced imaging technologies and operating rooms. These resources are essential for accurately diagnosing and effectively administering placental stem cell therapies for neurological disorders.
The North American Placental Stem Cell Therapy For Neurological Disorders Market Holds A Significant Regional Revenue Share
The North American placental stem cell therapy for neurological disorders market is expected to register the highest market share in revenue soon. Increasing awareness of placental stem cell therapies and their potential benefits has driven patient demand in North America. Patients with neurological disorders are actively seeking alternative treatments, contributing to market growth. Collaborations between academic institutions, healthcare providers, and biotechnology companies have led to establishing specialized centres for placental stem cell therapy in neurological disorders, fostering advancements and accessibility.
In addition, Asia Pacific is estimated to grow rapidly in the global placental stem cell therapy for neurological disorders market. The region benefits from a regulatory framework that facilitates the development and commercialization of regenerative therapies. Regulatory agencies, such as those in this region, have established clear pathways for approving stem cell therapies, providing a conducive environment for market growth.
Recent Developments
- In Jan 2021, Celularity Inc. made an announcement regarding the release of the 100th cord blood stem cell unit by its Lifebank subsidiary. This unit will be utilised in an autologous cord blood transplant procedure, specifically aimed at treating an eight-year-old youngster who has been diagnosed with autism spectrum disorder.
Placental Stem Cell Therapy for Neurological Disorders Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2022 |
USD 384.09 Mn |
|
Revenue Forecast In 2031 |
USD 2,049.44 Mn |
|
Growth Rate CAGR |
CAGR of 20.6 % from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Mn and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Type, and End-User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Mesoblast Ltd., Pluristem Therapeutics, ReNeuron Group, AthersysInc., Cordlife India, LifeCell International Pvt. Ltd, Cryo-Cell International Inc., CBR Systems, Cellularity Inc., Cynata |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
